Discontinued Product

Unfortunately R-(+)-Atenolol (Cat. No. 0392) has been withdrawn from sale for commercial reasons.
Cat.No. 0392 - R-(+)-Atenolol | CAS No. 56715-13-0
Description: Inactive isomer
Chemical Name: R-(+)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide

Biological Activity

Inactive enantiomer.

Technical Data

M. Wt 266.34
Storage Store at RT
CAS Number 56715-13-0

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Preparing Stock Solutions

The following data is based on the product molecular weight 266.34. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.75 mL 18.77 mL 37.55 mL
5 mM 0.75 mL 3.75 mL 7.51 mL
10 mM 0.38 mL 1.88 mL 3.75 mL
50 mM 0.08 mL 0.38 mL 0.75 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service.
Safety Datasheet


References are publications that support the products' biological activity.

Stoschitzky et al (1993) Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies. Chirality 5 15 PMID: 8383518

Merck Index 12 892 PMID:

View Related Products by Target

Keywords: R-(+)-Atenolol, supplier, Adrenergic, Beta-1, Receptors, Adrenergic, Beta-1, Receptors, Tocris Bioscience

Citations for R-(+)-Atenolol

Citations are publications that use Tocris products.

Currently there are no citations for R-(+)-Atenolol.

Reviews for R-(+)-Atenolol

There are currently no reviews for this product. Be the first to review R-(+)-Atenolol and earn rewards!

Have you used R-(+)-Atenolol?

Submit a review and receive an Amazon gift card.

$10US/$10CAN/€7/£6 gift card for a review without an image

$25US/$25CAN/€18/£15 gift card for a review with an image

*Offer only valid in the USA / Canada, UK and Europe

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling

Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.


Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.